论文部分内容阅读
目的：研究新癌标ＣＹＥＲＡ２１－１ 对非小细胞肺癌，特别是鳞癌在临床诊断和予后监测上的意义。方法：测定于１９９６ 年至１９９７ 年４ 月间住院的９２ 例患者（肺癌６４ 例，良性肺疾病２８ 例）的血清ＣＹＥＲＡ２１－１ 和ＣＥＡ的值，并比较肺癌的不同组织类型、临床分期和治疗前后的差异。结果：血清ＣＹＥＲＡ２１－１ 和ＣＥＡ 的阳性率在肺癌中分别为４２．１９％ 和３４．３５％ 显著地高于良性肺疾病组， ＣＹＥＲＡ２１－１ 值和阳性率在肺鳞癌显著地高于腺癌组（Ｐ＜０．０１），肺鳞癌Ⅳ期高于Ⅲ期（Ｐ＜ ０．０５），治疗后值下降。结论：血清ＣＹＥＲＡ２１－１ 对肺癌、特别是对鳞癌是一个有用的诊断和监测标记物。
Objective: To study the significance of the new cancer marker CYERA21-1 in clinical diagnosis and post-monitoring of non-small cell lung cancer, especially squamous cell carcinoma. METHODS: Serum CYERA21-1 and CEA values were determined in 92 patients (64 lung cancers, 28 benign lung diseases) hospitalized between 1996 and April 1997, and compared for different tissue types, clinical stages, and treatments for lung cancer. Before and after the difference. Results: The positive rates of serum CYERA21-1 and CEA in lung cancer were 42.19% and 34.35%, respectively, significantly higher than those in the benign lung disease group. The CYERA21-1 value and positive rate were significantly higher in lung squamous cell carcinoma than in the gland. In the cancer group (P<0.01), the stage IV squamous cell carcinoma was higher than stage III (P<0.05), and decreased after treatment. Conclusion: Serum CYERA21-1 is a useful diagnostic and monitoring marker for lung cancer, particularly squamous cell carcinoma.